<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00872651</url>
  </required_header>
  <id_info>
    <org_study_id>C-08-074</org_study_id>
    <nct_id>NCT00872651</nct_id>
  </id_info>
  <brief_title>Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible patients will be randomized in a 1.1 ratio to receive Travoprost 0.004%/timolol 0.5%&#xD;
      once daily or Latanoprost 0.005%/Timolol 0.5% once a day for 8 Weeks. The study treatments&#xD;
      will be compared for mean diurnal intraocular pressure (IOP) change from baseline at Week 8.&#xD;
&#xD;
      Safety parameters measured at 4 study visits: ocular signs, visual acuity, dilated fundus,&#xD;
      cardiovascular parameters (blood pressure and pulse), and adverse events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure (IOP)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mean Diurnal Intraocular Pressure (IOP) (averaged at 9 AM, 11 AM and 4 PM) change from baseline at Week 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mean IOP change from baseline at 9 AM at Week 2 and Week 6 visits and at 9 AM, 11 AM and 4 PM at Week 8 visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Travoprost 0.004%/Timolol 0.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost 0.004%/Timolol 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost 0.005% / Timolol 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Latanoprost 0.005% / Timolol 0.5%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost 0.004%/Timolol 0.5%</intervention_name>
    <description>Travoprost 0.004%/Timolol 0.5%</description>
    <arm_group_label>Travoprost 0.004%/Timolol 0.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost 0.005% / Timolol 0.5%</intervention_name>
    <description>Latanoprost 0.005% / Timolol 0.5%</description>
    <arm_group_label>Latanoprost 0.005% / Timolol 0.5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of either sex and any race, 18 years of age or older, diagnosed with open&#xD;
             angle glaucoma or ocular hypertension who are not sufficiently responsive to topical&#xD;
             beta-blockers or prostaglandin analogues.&#xD;
&#xD;
          -  Patients must meet the following IOP criteria in at least one eye. For each qualifying&#xD;
             eye, the mean IOP should be ≥21 mmHg at 9 AM and 11 AM time points at the eligibility&#xD;
             visit&#xD;
&#xD;
          -  The mean IOP in either eye at the eligibility visit must not be greater than 35 mmHg&#xD;
             at any time point.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any form of glaucoma other than open-angle glaucoma (with or without a&#xD;
             pigment dispersion or pseudoexfoliation component) or ocular hypertension.&#xD;
&#xD;
          -  Patients with iridocorneal angle Shaffer grade &lt; 2 (extreme narrow angle with complete&#xD;
             or partial closure) angle in either eye, as measured by gonioscopy&#xD;
&#xD;
          -  Patients with a cup/disc ratio greater than 0.80 (horizontal or vertical measurement)&#xD;
             in either eye.&#xD;
&#xD;
          -  Patients with severe central visual field loss in either eye. Severe central field&#xD;
             loss is defined as a sensitivity of ≤ 10 dB in at least 2 of the 4 visual field test&#xD;
             points closest to the point of fixation.&#xD;
&#xD;
          -  Current chronic, recurrent or severe inflammatory eye disease (e.g., scleritis,&#xD;
             uveitis, herpes keratitis), or current other severe ocular pathology (including severe&#xD;
             dry eye) that would affect the conduct of the study.&#xD;
&#xD;
          -  History of ocular trauma within the past 6 months.&#xD;
&#xD;
          -  Intraocular surgery within the past 3 months.&#xD;
&#xD;
          -  Ocular laser surgery within the past 3 months.&#xD;
&#xD;
          -  Best-corrected visual acuity score worse than 55 ETDRS letters read (equivalent to&#xD;
             approximately 20/80 Snellen or 0.25 decimal)&#xD;
&#xD;
          -  Current ocular infection or inflammation, or history of ocular infection or&#xD;
             inflammation within the past 3 months, as determined by patients' history and/or&#xD;
             examination.&#xD;
&#xD;
          -  History of or current clinically relevant or progressive retinal disease, such as&#xD;
             retinal degeneration, diabetic retinopathy or retinal detachment.&#xD;
&#xD;
          -  Any abnormality preventing reliable applanation tonometry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>February 25, 2009</study_first_submitted>
  <study_first_submitted_qc>March 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2009</study_first_posted>
  <last_update_submitted>March 27, 2013</last_update_submitted>
  <last_update_submitted_qc>March 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>intraocular pressure</keyword>
  <keyword>travoprost/timolol</keyword>
  <keyword>timolol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

